Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-CART-007 in relapsed/refractory T-ALL/LBL
NCT04984356Phase 1Completed
- Sponsor
- Wugen
- Start
- Jan 2022
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of soficabtagene geleucel in t-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LL), sponsored by Wugen. Primary endpoints: Adverse Events at 24 months and Maximum Tolerated Dose at 28 days. Started Jan 2022; status: completed.
02
Drugs
soficabtagene geleucel
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT04984356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984356.